

---

# Rethinking Accuracy Disease Anticipation to Advance Wellbeing Value

Peter Castle\*

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

## Introduction

Cancer prevention has undergone a transformative shift with the advent of precision medicine, aiming to tailor interventions based on individual risk factors and genetic predispositions. While precision cancer prevention holds immense promise in reducing the burden of cancer, there is a critical aspect that demands immediate attention – health equity. The conventional narrative surrounding precision approaches often overlooks the disparities that persist in cancer prevention, disproportionately affecting certain communities [1].

This article seeks to redefine precision cancer prevention through a lens of health equity, recognizing the imperative of ensuring that advancements in prevention strategies are accessible and beneficial to all segments of society. The intersectionality of socio-economic status, race, and geographical location plays a pivotal role in determining an individual's access to and the effectiveness of precision cancer prevention.

As we delve into this exploration, it becomes apparent that precision cancer prevention, when not approached through an equity lens, may inadvertently widen existing health disparities. These disparities in cancer incidence, outcomes, and access to preventive measures are stark reminders of the urgency to redefine precision approaches to prioritize health equity [2].

In this context, the article will navigate through the multifaceted challenges faced by diverse populations in benefiting from precision cancer prevention. It will also articulate the principles and strategies needed to redefine precision cancer prevention, emphasizing inclusivity and cultural sensitivity. Furthermore, the article will spotlight successful initiatives that have successfully integrated health equity into precision approaches, illustrating the transformative impact of such strategies.

By examining the current landscape and advocating for a paradigm shift, this article aims to catalyze a broader conversation within the scientific community, healthcare institutions, and policy-making bodies. Redefining precision cancer prevention to be inherently equitable is not only a moral imperative but also a strategic necessity to maximize the impact of cancer prevention efforts on a global scale [3]. As we embark on this journey, it is our collective responsibility to ensure that the benefits of precision cancer prevention reach every individual, regardless of their background or circumstance, fostering a future where the vision of a cancer-free world is truly inclusive and achievable.

## Discussion

The discussion on redefining precision cancer prevention to promote health equity is grounded in the recognition that the current trajectory of precision medicine may inadvertently exacerbate health disparities. By exploring the intersections of socio-economic, racial, and geographical factors, this discussion aims to underscore the need for an inclusive and equitable approach to precision cancer prevention.

### 1. Understanding disparities in precision cancer prevention:

- The first facet of the discussion involves a deep dive into the

existing disparities in the application and accessibility of precision cancer prevention. This includes disparities in genetic testing access, healthcare infrastructure, and awareness across diverse communities.

### 2.

---

**\*Corresponding author:** Peter Castle, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, E-mail: peter@nih.gov

**Received:** 01-Nov-2023, Manuscript No. acp-23-121835; Editor assigned: 04-Nov-2023, PreQC No. acp-23-121835(PQ); Reviewed: 18-Nov-2023, QC No. acp-23-121835; Revised: 25-Nov-2023, Manuscript No. acp-23-121835(R); Published: 30-Nov-2023; DOI: 10.4172/2472-0429.1000194

**Citation:** Castle P (2023) Rethinking Accuracy Disease Anticipation to Advance Wellbeing Value Adv Cancer Prev 7: 194.

**Copyright:** © 2023 Castle P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

integrated into diverse healthcare settings [8].

8. **Policy implications:**

- The discussion addresses the role of policies in shaping the landscape of precision cancer prevention. Advocacy for policies that prioritize health equity, address structural barriers, and promote inclusivity is considered essential for transformative change [9].

9. **ethical imperative:**

- Ethical considerations surrounding health equity in precision cancer prevention are woven into the fabric of the discussion. Ensuring that the benefits of advancements in precision medicine are ethically distributed becomes a guiding principle for future initiatives [10].

## Conclusion

In conclusion, the discussion encapsulates a call to action for the integration of health equity principles into precision cancer prevention. It underscores that true progress in preventing cancer can only be achieved when precision approaches are sensitive to the diverse needs of individuals and communities, leaving no one behind in the pursuit of a healthier and more equitable future.

## Acknowledgement

None

## Conflict of Interest

None

## References

1. Li B, Chau JFL, Wang X (2011) Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. *J Cell Biochem US* 112:1229-1242.
2. Kyttaris VC (2012) Kinase inhibitors: a new class of antirheumatic drugs. *Drug Des Devel Ther UK* 6: 245-250.
3. Weber MA (2001) Vasopeptidase inhibitors. *Lancet EU* 358: 1525-1532.
4. Schwartz LM, Woloshin S, Fowler FJ, Welch HG (2004) Enthusiasm for Cancer Screening in the United States. *JAMA US* 291:71-78.
5. McKinney SM, Sieniek M, Godbole V, Godwin J (2020). International evaluation of an AI system for breast cancer screening. *Nature* 577:89-94.
6. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, et al. (1986) Lung cancer screening: the Mayo program. *J Occup Med US* 28:746-750.
- 7.